PATH moving, November 9 FDA end of review meeting
Following an end-of-review meeting with the FDA on November 9th to discuss the questions the FDA raised in its August's Complete Response Letter (CRL), NuPathe (PATH) expects to determine the timing of the resubmission of its NDA and the commercial launch of its migraine patch. In addition to NP101, NuPathe (PATH) has two additional proprietary product candidates: NP201 for the continuous symptomatic treatment of Parkinson’s disease, for which the company plans to partner, and NP202, in preclinical development, for the long-term treatment of schizophrenia and bipolar disorder. NuPathe’s initial public offering of common stock in August 2010 raised $50 million in gross proceeds. Safeguard has deployed $18.3 million of capital in NuPathe (PATH) since September 2006 and owns 18% of its outstanding common shares. "
